score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61K	0.5537	475.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0.0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0	313.0	0.623	1.0	NRAS p.Q61K (Missense)	1.0	MEL-IPI_Pat47	MEL-IPI_Pat47-Tumor-SM-4DK28	MEL-IPI_Pat47-Normal-SM-53U5U
Biologically Relevant				Somatic Variant	FGFR1	Missense	p.P25L	0.6142	127.0	0.0	0.0																					0	440.0	0.5795	1.0	FGFR1 p.P25L (Missense)		MEL-IPI_Pat47	MEL-IPI_Pat47-Tumor-SM-4DK28	MEL-IPI_Pat47-Normal-SM-53U5U
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.E596V	0.3889	468.0	0.0	0.0																					0	0.0	0.0	0.0	FGFR2 p.E596V (Missense)		MEL-IPI_Pat47	MEL-IPI_Pat47-Tumor-SM-4DK28	MEL-IPI_Pat47-Normal-SM-53U5U
Biologically Relevant				Microsatellite Stability	Supporting variants		PRDM2 p.703_704insP (Insertion), MSH3 p.AAAAAA52del (Deletion), MSH3 p.PPA66del (Deletion)																									0				Supporting variants: PRDM2 p.703_704insP (Insertion), MSH3 p.AAAAAA52del (Deletion), MSH3 p.PPA66del (Deletion)		MEL-IPI_Pat47		
Biologically Relevant				Mutational Signature	COSMIC Signature 7	version 2	0.558																									0				COSMIC Signature (version 2) 7 (56%)		MEL-IPI_Pat47		
